Welcome to our dedicated page for L A M Y news (Ticker: LMMY), a resource for investors and traders seeking the latest updates and insights on L A M Y stock.
Exousia Bio, Inc., formerly L A M Y, reports developments tied to its transition into an exosome-based biotechnology company focused on cancer therapy. Company news has covered the completed acquisition of Exousia AI, exclusive worldwide exosome technology licenses, nucleic-acid loading and targeted-delivery platforms, and therapeutic applications involving cancer stem cells, glioblastoma, pancreatic cancer, and viral infections.
Earlier LMMY updates also documented LAMY's TwoPlus1® gamified financial education platform, Web3 education initiatives, NFTs, digital assets, and partnerships connected to metaverse-based learning and green finance education.
LAMY (OTC:LMMY) has announced major developments in its education-gaming integration platform. The company's flagship product, TwoPlus1, combines financial education with gaming technology, featuring AI-powered personalized learning experiences and a virtual economic ecosystem.
Key developments include:
- Integration of AI technology for personalized learning and virtual asset trading recommendations
- Strategic partnership discussions with global EdTech companies and game developers
- Projected 300% user growth in European and Asian markets over next two years
- Revenue generation through virtual asset transaction commissions, subscriptions, and advertising
The platform allows users to trade virtual assets in a safe environment while learning financial literacy. LAMY plans to further enhance its ecosystem through continued investment in AI and blockchain technologies.